april
reuter
health
megan
rauscher
health
offici
center
diseas
control
prevent
cdc
announc
initi
design
refocu
hiv
prevent
effort
estim
peopl
unit
state
know
infect
hiv
tragic
get
appropri
treatment
intoler
situat
cdc
director
dr
juli
gerberd
told
report
prevent
effort
make
kind
ongo
progress
would
expect
given
recent
advanc
hiv
test
said
new
initi
take
advantag
fdalicens
rapid
hiv
test
perform
set
std
clinic
shelter
drug
treatment
center
correct
facil
fact
result
avail
roughli
minut
dr
gerberd
said
mean
patient
nt
come
followup
visit
get
test
result
announc
cdc
guidelin
would
longer
includ
requir
extens
counsel
prerequisit
get
hiv
test
behavior
counsel
still
critic
import
dr
gerberd
said
medic
environ
barrier
get
test
done
mani
clinician
nt
know
kind
counsel
simpli
time
remov
requir
condit
test
part
initi
cdc
work
clinician
make
hiv
test
routin
compon
medic
care
mean
get
physician
ask
simpl
question
inject
drug
use
unsaf
sex
offer
hiv
test
dr
gerberd
said
matern
hiv
test
also
big
compon
initi
believ
strongli
case
perinat
transmiss
realli
repres
failur
public
health
system
want
mother
test
hiv
infect
dr
gerberd
said
cdc
recommend
optout
approach
pregnant
women
test
hiv
offer
test
goal
make
hiv
test
routin
part
perinat
care
dr
gerberd
said
ad
go
everyth
ensur
children
born
infect
mother
access
antiretrovir
therapi
dr
gerberd
emphas
cdc
recommend
mandatori
hiv
test
group
peopl
circumst
simpli
treat
hiv
test
like
test
would
normal
part
routin
care
said
part
initi
cdc
also
put
focu
hivinfect
popul
past
prevent
effort
gone
toward
address
behavior
uninfect
peopl
put
risk
exposur
need
continu
dr
gerberd
said
nt
put
much
emphasi
hivinfect
peopl
compon
prevent
paradigm
perhap
said
import
make
sure
partner
hivinfect
patient
access
test
sourc
morb
mortal
wkli
rep
mmwr
april
reuter
health
ori
twerski
canada
medmira
inc
said
receiv
clearanc
us
food
drug
administr
fda
market
reveal
rapid
antibodi
test
rival
firm
orasur
technolog
inc
bethlehem
pennsylvania
recent
clearanc
rapid
hiv
antibodi
test
accord
medmira
reveal
test
becom
fastest
antibodi
test
clear
fda
test
shown
equival
better
convent
hiv
diagnost
test
typic
take
day
conduct
firm
ad
april
reuter
health
vaccin
compani
joint
ventur
comput
scienc
corpor
porton
intern
said
investig
cellcultur
smallpox
vaccin
ccsv
induc
fewer
side
effect
histor
dryvax
vaccin
phase
trial
volunt
volunt
exhibit
posit
respons
either
ccsv
dryvax
calflymph
produc
smallpox
vaccin
recent
complet
trial
dynport
said
incid
vaccinerel
fatigu
applicationsit
rash
increas
temperatur
headach
lymphang
nausea
least
less
common
among
volunt
receiv
ccsv
rather
dryvax
april
reuter
lisa
richwin
offici
urg
precaut
keep
blood
suppli
free
sever
acut
respiratori
syndrom
sar
respiratori
ill
although
said
know
whether
viru
caus
transmit
blood
us
food
drug
administr
fda
advis
blood
bank
ask
potenti
donor
question
aim
identifi
peopl
could
infect
viru
caus
sar
experienc
symptom
peopl
alreadi
sick
sar
would
normal
turn
away
blood
bank
anyway
sinc
one
good
health
permit
donat
blood
fda
said
new
question
focu
find
peopl
may
face
elev
risk
sar
recent
visit
known
highrisk
area
expos
someon
ill
peopl
visit
area
high
number
sar
case
symptom
ban
give
blood
day
return
unit
state
fda
said
list
area
current
includ
china
singapor
hanoi
acut
case
sar
base
symptom
travel
histori
exclud
donat
blood
day
symptom
clear
treatment
complet
fda
guidelin
said
among
fda
suggest
blood
bank
encourag
peopl
give
blood
contact
collect
agenc
develop
sar
within
day
postdon
blood
potenti
expos
infect
peopl
quarantin
fda
said
fda
recommend
new
bloodcollect
guidelin
put
place
within
day
precaut
scientist
work
learn
sar
viru
known
case
sar
transmiss
via
blood
product
occur
fda
said
howev
detect
gene
possibl
caus
viru
blood
report
patient
sar
also
viral
infect
person
sar
could
potenti
viru
blood
earli
infect
without
symptom
fda
statement
said
therefor
transfus
transmiss
sar
may
possibl
fda
said
agenc
estim
potenti
donor
defer
new
guidelin
editor
comment
recommend
assum
coronaviru
caus
sar
found
blood
would
present
blood
day
exposur
without
develop
diseas
would
blood
longer
day
clear
symptom
assumpt
reason
basi
present
inform
howev
basi
evolv
observ
eg
presenc
viru
stool
urin
nasopharynx
long
day
onset
symptom
peiri
j
chu
c
cheng
v
c
c
et
al
prospect
studi
clinic
progress
viral
load
sar
associ
coronaviru
pneumonia
commun
outbreak
summari
avail
http
wwwwho
intcsrsarsprospectivestudyenindex
html
recommend
may
need
modifi
may
reuter
health
san
diego
base
compani
said
engin
human
antibodi
neutral
anthrax
toxin
rat
could
potenti
protect
peopl
expos
sometim
deadli
bacteria
potenc
antibodi
exhibit
extrem
high
dr
phillip
morrow
research
avanir
pharmaceut
said
statement
encourag
data
plan
develop
antibodi
use
prophylact
therapeut
drug
prevent
treat
anthrax
infect
avanir
said
antibodi
call
act
molecul
anthrax
toxin
use
get
cell
compani
present
find
vaccin
meet
maryland
said
plan
test
antibodi
guinea
pig
next
editor
comment
avail
effect
antitoxin
would
welcom
might
effect
advanc
clinic
case
poor
respons
antibiot
therapi
furthermor
might
effect
bioterrorismassoci
strain
engin
resist
multipl
antibiot
